Actavis acquired Forest Laboratories for approximately $25B ($28.38 per share in cash and stock). Deal announced February 2014, closed June 2014. The acquisition gave Actavis Forest's branded pharmaceutical portfolio including Namenda (memantine) and pipeline assets.